Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
Margherita RiminiGianluca MasiSara LonardiFederico NichettiTiziana PressianiDaniele LavacchiLucchetti JessicaGuido GiordanoMario ScartozziEmiliano TamburiniAlessandro PastorinoIlario Giovanni RapposelliBruno DanieleErika MartinelliIngrid GarajovaGiuseppe AprileMarta SchirripaVincenzo FormicaFrancesca SalaniCostanza WinchlerFrancesca BergamoRita BalsanoEleonora GusmaroliAngotti LorenzoMatteo LandriscinaAndrea PrettaIlaria TomaChiara PirroneAnna DianaFrancesco LeoneOronzo BrunettiGiovanni BrandiSilvio Ken GarattiniMaria Antonietta SatolliFederico RossariLorenzo FornaroMonica NigerValentina ZanusoAntonio De RosaFrancesca RattiLuca AldrighettiFilippo De BraudSilvia FotiMario Domenico RizzatoCaterina VivaldiCascinu StefanoLorenza RimassaLorenzo AntonuzzoStefano CascinuPublished in: Targeted oncology (2024)
In line with the results of the TOPAZ-1 trial, adding durvalumab to cisplatin/gemcitabine has been confirmed to confer a survival benefit in terms of OS and PFS in a real-world setting of patients with advanced BTC.